Results 11 to 20 of about 191,109 (267)
Human Vaccines & Immunotherapeutics, 2023 This post-hoc analysis compared the receptor-binding domain (RBD)-specific and pseudovirus neutralizing antibodies against the wild-type SARS-CoV-2 strain elicited by one or two doses (56-d interval) of Ad5-nCoV vaccine regimen (NCT04341389 and ...
Jia-Lu Feng +9 more
doaj +1 more source
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. [PDF]
PLoS Pathogens, 2017 Human cytomegalovirus (HCMV) is an important, ubiquitous pathogen that causes severe clinical disease in immunocompromised individuals, such as organ transplant recipients and infants infected in utero.
Anna Bootz +8 more
doaj +1 more source
Virology Journal, 2022 Background Seneca Valley virus (SVV) is a picornavirus that causes vesicular disease in swine. Clinical characteristics of the disease are similar to common viral diseases such as foot-and-mouth disease virus, porcine vesicular disease virus, and ...
Wei Wen +5 more
doaj +1 more source
Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. [PDF]
PLoS ONE, 2014 Recent immune correlates analysis from the RV144 vaccine trial has renewed interest in the role of non-neutralizing antibodies in mediating protection from infection.
Anne-Sophie Dugast +11 more
doaj +1 more source
Viruses, 2012 The immune response against some viral pathogens, in particular those causing chronic infections, is often ineffective notwithstanding a robust humoral neutralizing response.
Roberto Burioni +8 more
doaj +1 more source
Neutralizing Antibodies against SARS-CoV2
Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2023 Coronavirus disease 2019 (COVID-19) is an illness due to a novel coronavirus which is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Though this virus is recently identified in 2019, it is closely related to other coronaviruses namely SARS-
Prachi Athavale +4 more
doaj +1 more source
Cross-reactive broadly neutralizing antibodies: timing is everything
Frontiers in Immunology, 2012 The recent surge of research into new broadly neutralizing antibodies in HIV-1 infection has recharged the field of HIV-1 vaccinology. In this review we discuss the currently known broadly neutralizing antibodies and focus on factors that may shape these
Zelda eEuler +2 more
doaj +1 more source
ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization
Viruses, 2019 Infection with Zika virus (ZIKV) came first to public attention after it was found to be associated with congenital microcephaly during the outbreak in Brazil (2015–2016). Diagnosis of ZIKV suffers from extensive cross-reactivity with other Flaviviruses,
Sami Akhras +4 more
doaj +1 more source
PLoS ONE, 2019 Vaccines that elicit broadly cross-neutralizing antibodies, including antibodies that target the conserved stem of hemagglutinin (HA), are being developed as a strategy for next-generation influenza vaccines that protect against influenza across multiple
Wei Wang +11 more
doaj +1 more source
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Frontiers in Microbiology, 2023 COVID-19 pandemic is a global public health emergency. Despite extensive research, there are still few effective treatment options available today. Neutralizing-antibody-based treatments offer a broad range of applications, including the prevention and ...
Mingtao Liu +11 more
doaj +1 more source